Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
European Journal of Pharmacology
|
November 7, 2012
The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model
Henrik Ponten, Johan Kullingsjö, Clas Sonesson, et al.
Scandinavian Journal of Psychology
|
August 14, 2003
Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine
Ola Gefvert, Leif H Lindström, Nicholas Waters, et al.
Brain Research. Developmental Brain Research
|
March 15, 2005
Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period
Henrik Ponten, Kirsten Sönniksen, Therése Abrahamsson, et al.
Frontiers in Microbiology
|
July 13, 2018
Absence of Curli in Soil-Persistent <i>Escherichia coli</i> Is Mediated by a C-di-GMP Signaling Defect and Suggests Evidence of Biofilm-Independent Niche Specialization
Yinka M Somorin, Tara Vollmerhausen, Nicholas Waters, et al.
Clinical Pharmacology in Drug Development
|
June 12, 2021
First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers
Erik Rein-Hedin, Folke Sjöberg, Susanna Waters, et al.
European Journal of Pharmacology
|
July 30, 2010
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten, Johan Kullingsjö, Sören Lagerkvist, et al.
European Journal of Pharmacology
|
November 19, 2009
The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties
Tino Dyhring, Elsebet Ø Nielsen, Clas Sonesson, et al.
ACS Chemical Neuroscience
|
December 21, 2016
In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery
Susanna Waters, Peder Svensson, Johan Kullingsjö, et al.
The European Journal of Neuroscience
|
March 5, 2025
Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia
Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastian A Barrientos, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 3, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease
Susanna Waters, Clas Sonesson, Peder Svensson, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
European Journal of Pharmacology
|
November 7, 2012
The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model
Henrik Ponten, Johan Kullingsjö, Clas Sonesson, et al.
Scandinavian Journal of Psychology
|
August 14, 2003
Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine
Ola Gefvert, Leif H Lindström, Nicholas Waters, et al.
Brain Research. Developmental Brain Research
|
March 15, 2005
Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period
Henrik Ponten, Kirsten Sönniksen, Therése Abrahamsson, et al.
Frontiers in Microbiology
|
July 13, 2018
Absence of Curli in Soil-Persistent <i>Escherichia coli</i> Is Mediated by a C-di-GMP Signaling Defect and Suggests Evidence of Biofilm-Independent Niche Specialization
Yinka M Somorin, Tara Vollmerhausen, Nicholas Waters, et al.
Clinical Pharmacology in Drug Development
|
June 12, 2021
First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers
Erik Rein-Hedin, Folke Sjöberg, Susanna Waters, et al.
European Journal of Pharmacology
|
July 30, 2010
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten, Johan Kullingsjö, Sören Lagerkvist, et al.
European Journal of Pharmacology
|
November 19, 2009
The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties
Tino Dyhring, Elsebet Ø Nielsen, Clas Sonesson, et al.
ACS Chemical Neuroscience
|
December 21, 2016
In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery
Susanna Waters, Peder Svensson, Johan Kullingsjö, et al.
The European Journal of Neuroscience
|
March 5, 2025
Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia
Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastian A Barrientos, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 3, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease
Susanna Waters, Clas Sonesson, Peder Svensson, et al.
Page
of 3